NZ599643A - Substituted N-aryl pyridinones as fibrotic inhibitors - Google Patents
Substituted N-aryl pyridinones as fibrotic inhibitorsInfo
- Publication number
- NZ599643A NZ599643A NZ599643A NZ59964308A NZ599643A NZ 599643 A NZ599643 A NZ 599643A NZ 599643 A NZ599643 A NZ 599643A NZ 59964308 A NZ59964308 A NZ 59964308A NZ 599643 A NZ599643 A NZ 599643A
- Authority
- NZ
- New Zealand
- Prior art keywords
- fibrosis
- deuterium
- substituted
- collagen
- fibrotic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94513607P | 2007-06-20 | 2007-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ599643A true NZ599643A (en) | 2013-11-29 |
Family
ID=39731521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ599643A NZ599643A (en) | 2007-06-20 | 2008-06-20 | Substituted N-aryl pyridinones as fibrotic inhibitors |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US8383823B2 (enExample) |
| EP (1) | EP2170828B1 (enExample) |
| JP (1) | JP5587184B2 (enExample) |
| KR (2) | KR101583737B1 (enExample) |
| CN (2) | CN101842355A (enExample) |
| AU (1) | AU2008265595B2 (enExample) |
| CA (1) | CA2691379C (enExample) |
| DK (1) | DK2170828T3 (enExample) |
| ES (1) | ES2400026T3 (enExample) |
| HK (1) | HK1214251A1 (enExample) |
| IL (1) | IL202840A (enExample) |
| NZ (1) | NZ599643A (enExample) |
| WO (1) | WO2008157786A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| MX2007009796A (es) | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
| US20090131485A1 (en) * | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| US20110313004A1 (en) * | 2008-12-04 | 2011-12-22 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| WO2010132864A1 (en) * | 2009-05-15 | 2010-11-18 | Intermune, Inc. | Methods of treating hiv patients with anti-fibrotics |
| TWI434833B (zh) * | 2009-06-03 | 2014-04-21 | Intermune Inc | 用於合成吡非尼酮（ｐｉｒｆｅｎｉｄｏｎｅ）的改良方法 |
| US20110053968A1 (en) * | 2009-06-09 | 2011-03-03 | Auspex Pharmaceuticals, Inc. | Aminopyrimidine inhibitors of tyrosine kinase |
| CN101921225B (zh) * | 2009-06-11 | 2013-04-03 | 北京凯得尔森生物技术有限公司 | 吡啡尼酮类化合物、其制备方法和应用 |
| CN102639700A (zh) | 2009-09-30 | 2012-08-15 | 哈佛大学校长及研究员协会 | 通过调节自噬增强基因产物调节自噬的方法 |
| US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| HUE058753T2 (hu) * | 2011-01-31 | 2022-09-28 | Avalyn Pharma Inc | Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik |
| BR112013022766A2 (pt) * | 2011-03-08 | 2016-12-06 | Auspex Pharmaceuticals Inc | método de administração de d-pirfenidona e kit |
| AU2012258575B2 (en) * | 2011-05-25 | 2017-03-02 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| MX2011007675A (es) | 2011-07-19 | 2012-07-11 | Cell Therapy And Technology S A De C V | Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas. |
| HUE062616T2 (hu) | 2011-09-08 | 2023-11-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásaik |
| BR112014012288A2 (pt) | 2011-11-22 | 2017-05-23 | Intermune Inc | métodos para diagnosticar e tratar fibrose pulmonar idiopática |
| MX346763B (es) | 2012-03-28 | 2017-03-31 | Cell Therapy And Tech S A De C V | Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné. |
| US12226407B2 (en) | 2012-07-24 | 2025-02-18 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| EP2882426A1 (en) * | 2012-08-13 | 2015-06-17 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for treatment of cystic fibrosis |
| MX356551B (es) | 2012-08-23 | 2018-06-04 | Grupo Medifarma S A De C V Star | Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné. |
| CA2819967C (en) * | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Use of pirfenidone concomitantly with ciprofloxacin |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| FI3932932T3 (fi) | 2013-03-13 | 2025-10-15 | Sage Therapeutics Inc | Neuroaktiivisia steroideja ja niiden käyttömenetelmiä |
| CN112057457A (zh) * | 2013-03-13 | 2020-12-11 | 萨奇治疗股份有限公司 | 神经活性类固醇、组合物、及其用途 |
| JP7066321B2 (ja) | 2014-01-10 | 2022-05-13 | アヴァリン ファーマ インク． | エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用 |
| US20160331734A1 (en) * | 2014-01-24 | 2016-11-17 | Auspex Pharmaceuticals, Inc. | Substituted n-aryl pyridinones |
| MX2016010213A (es) | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| US20150284327A1 (en) * | 2014-04-04 | 2015-10-08 | Auspex Pharmaceuticals, Inc. | Oxindole inhibitors of tyrosine kinase |
| WO2015171345A1 (en) * | 2014-04-30 | 2015-11-12 | Auspex Pharmaceuticals, Inc. | N-aryl pyridinones modulators of fibrosis and/or collagen infiltration |
| JP6628745B2 (ja) | 2014-06-18 | 2020-01-15 | セージ セラピューティクス， インコーポレイテッド | オキシステロールおよびその使用方法 |
| SG10202010157VA (en) * | 2015-02-10 | 2020-11-27 | Axsome Therapeutics Inc | Pharmaceutical compositions comprising meloxicam |
| WO2017007832A1 (en) | 2015-07-06 | 2017-01-12 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| DK3812392T3 (da) | 2015-07-06 | 2025-07-21 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| PT3319611T (pt) | 2015-07-06 | 2021-04-22 | Sage Therapeutics Inc | Oxisteróis e métodos de utilização dos mesmos |
| CN105315198A (zh) * | 2015-11-02 | 2016-02-10 | 重庆康乐制药有限公司 | 一种吡非尼酮的晶型及其制备方法 |
| CN105330598B (zh) * | 2015-12-02 | 2017-11-14 | 新发药业有限公司 | 一种吡非尼酮的制备方法 |
| EP3868374A3 (en) * | 2016-03-22 | 2021-11-10 | Mayo Foundation for Medical Education and Research | Using fatty acid synthase inhibitors to treat fibrosis |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| ES2921010T3 (es) | 2016-04-01 | 2022-08-16 | Sage Therapeutics Inc | Oxisteroles y procedimientos de uso de los mismos |
| US10945999B2 (en) | 2016-04-08 | 2021-03-16 | Quretech Bio Ab | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis |
| WO2017193046A1 (en) | 2016-05-06 | 2017-11-09 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| WO2018009867A1 (en) | 2016-07-07 | 2018-01-11 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| MA46351A (fr) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | Oxystérols substitués en c7 et procédés en tant que modulateurs nmda |
| KR102521573B1 (ko) | 2016-10-18 | 2023-04-14 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| DK3529257T3 (da) | 2016-10-18 | 2023-08-07 | Sage Therapeutics Inc | Oxysteroler og fremgangsmåder til anvendelse deraf |
| CN106748984A (zh) * | 2016-11-22 | 2017-05-31 | 斯芬克司药物研发（天津）股份有限公司 | 6‑羟甲基‑1‑苯基吡啶‑2‑酮及其制备方法与应用 |
| CA3108048A1 (en) * | 2017-07-31 | 2019-02-07 | Washington University | Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection |
| MX366086B (es) | 2017-08-15 | 2019-06-27 | Cell Therapy And Tech S A De C V | Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel. |
| CN108285431B (zh) * | 2018-03-23 | 2021-04-09 | 北京康蒂尼药业股份有限公司 | 一种吡非尼酮有关物质及其制备方法和用途 |
| MX368750B (es) | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
| IL319182A (en) * | 2018-09-14 | 2025-04-01 | Puretech Lyt 100 Inc | Deuterium-enriched pirfenidone and methods of using it |
| WO2022010925A1 (en) * | 2020-07-06 | 2022-01-13 | Puretech Lyt 100, Inc. | Methods of treating diseases and disorders with deupirfenidone |
| US20250114341A1 (en) | 2018-09-14 | 2025-04-10 | Puretech Lyt 100, Inc. | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
| US20230129866A1 (en) | 2020-03-13 | 2023-04-27 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| EP4121049A4 (en) * | 2020-03-18 | 2024-04-03 | Puretech Lyt 100, Inc. | Methods of treating lymphedema with deupirfenidone |
| AU2023205787A1 (en) * | 2022-01-05 | 2024-06-13 | Puretech Lyt 100, Inc. | Methods of treating idiopathic pulmonary fibrosis with deupirfenidone |
| CN114957106B (zh) * | 2022-05-23 | 2024-01-30 | 湖北工程学院 | 药物吡非尼酮的流动相自动合成方法 |
| WO2026133157A1 (en) | 2024-12-16 | 2026-06-25 | Puretech Lyt 100, Inc. | Deupirfenidone for use for treating idiopathic pulmonary fibrosis |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02215719A (ja) | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
| US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
| US6294350B1 (en) * | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| DK1104760T3 (da) * | 1999-12-03 | 2003-06-30 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler |
| EP1134290A3 (en) * | 2000-03-14 | 2004-01-02 | Pfizer Products Inc. | Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| US20030194748A1 (en) * | 2000-05-29 | 2003-10-16 | Tohru Nagasaki | Method for labeling with tritium |
| US20060270618A1 (en) * | 2001-12-18 | 2006-11-30 | Dorian Bevec | Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases |
| AP1822A (en) | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| WO2004019863A2 (en) | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Combination therapy for treatment of fibrotic disorders |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| WO2005013917A2 (en) | 2003-02-28 | 2005-02-17 | Intermune, Inc. | Combination therapy for treating alphavirus infection and liver fibrosis |
| WO2004105684A2 (en) | 2003-05-16 | 2004-12-09 | Intermune, Inc. | Combination therapy for proliferative disorders |
| WO2005038056A1 (en) | 2003-10-14 | 2005-04-28 | Intermune, Inc. | Combination therapy for the treatment of viral diseases |
| WO2005040758A2 (en) | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| JP4072623B2 (ja) | 2004-03-09 | 2008-04-09 | 独立行政法人産業技術総合研究所 | ピリジン−ｎ−オキシド類の製造方法 |
| WO2005110478A2 (en) | 2004-04-13 | 2005-11-24 | Intermune, Inc. | Combination therapy for treating fibrotic disorders |
| AP2007004244A0 (en) * | 2005-05-10 | 2007-12-31 | Intermune Inc | Method of modulating stress-activated protein kinase system |
| US20080033011A1 (en) * | 2005-07-29 | 2008-02-07 | Concert Pharmaceuticals Inc. | Novel benzo[d][1,3]-dioxol derivatives |
| NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
| US20070203202A1 (en) | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| WO2008030382A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| US20080287508A1 (en) | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
| AU2008265595B2 (en) | 2007-06-20 | 2014-12-04 | PureTech LYT 100 Inc. | Substituted N-Aryl pyridinones as fibrotic inhibitors |
| US20090131485A1 (en) * | 2007-09-10 | 2009-05-21 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| US20110313004A1 (en) | 2008-12-04 | 2011-12-22 | Concert Pharmaceuticals, Inc. | Deuterated pyridinones |
| EP2389227A4 (en) | 2009-01-26 | 2012-08-08 | Intermune Inc | METHOD FOR THE TREATMENT OF ACUTE MYOCARDINE CARDS AND ASSOCIATED ILLNESSES THEREOF |
| CN102149682B (zh) | 2009-05-25 | 2012-12-05 | 中南大学 | 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途 |
| BR112013022766A2 (pt) | 2011-03-08 | 2016-12-06 | Auspex Pharmaceuticals Inc | método de administração de d-pirfenidona e kit |
| AU2012258575B2 (en) | 2011-05-25 | 2017-03-02 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
| US20160331734A1 (en) | 2014-01-24 | 2016-11-17 | Auspex Pharmaceuticals, Inc. | Substituted n-aryl pyridinones |
| WO2015171345A1 (en) | 2014-04-30 | 2015-11-12 | Auspex Pharmaceuticals, Inc. | N-aryl pyridinones modulators of fibrosis and/or collagen infiltration |
-
2008
- 2008-06-20 AU AU2008265595A patent/AU2008265595B2/en active Active
- 2008-06-20 EP EP08771632A patent/EP2170828B1/en active Active
- 2008-06-20 CA CA2691379A patent/CA2691379C/en active Active
- 2008-06-20 CN CN200880102512A patent/CN101842355A/zh active Pending
- 2008-06-20 WO PCT/US2008/067732 patent/WO2008157786A1/en not_active Ceased
- 2008-06-20 KR KR1020107001341A patent/KR101583737B1/ko active Active
- 2008-06-20 NZ NZ599643A patent/NZ599643A/xx unknown
- 2008-06-20 US US12/143,484 patent/US8383823B2/en active Active
- 2008-06-20 KR KR1020167000072A patent/KR101767849B1/ko active Active
- 2008-06-20 ES ES08771632T patent/ES2400026T3/es active Active
- 2008-06-20 JP JP2010513457A patent/JP5587184B2/ja active Active
- 2008-06-20 CN CN201510221701.2A patent/CN104892498A/zh active Pending
- 2008-06-20 DK DK08771632.0T patent/DK2170828T3/da active
-
2009
- 2009-12-20 IL IL202840A patent/IL202840A/en active IP Right Grant
-
2012
- 2012-10-29 US US13/663,188 patent/US8680123B1/en active Active
-
2013
- 2013-12-18 US US14/132,528 patent/US8969575B2/en active Active
-
2014
- 2014-04-30 US US14/266,048 patent/US9062001B2/en active Active
- 2014-08-08 US US14/455,339 patent/US8969576B2/en active Active
-
2015
- 2015-05-21 US US14/718,993 patent/US9504677B2/en active Active
-
2016
- 2016-02-24 HK HK16102071.0A patent/HK1214251A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008265595B2 (en) | 2014-12-04 |
| KR101583737B1 (ko) | 2016-01-11 |
| JP5587184B2 (ja) | 2014-09-10 |
| EP2170828B1 (en) | 2012-11-21 |
| IL202840A (en) | 2014-07-31 |
| EP2170828A1 (en) | 2010-04-07 |
| CN104892498A (zh) | 2015-09-09 |
| KR101767849B1 (ko) | 2017-08-11 |
| ES2400026T3 (es) | 2013-04-05 |
| US20140348928A1 (en) | 2014-11-27 |
| US20140235677A1 (en) | 2014-08-21 |
| CA2691379A1 (en) | 2008-12-24 |
| US8969575B2 (en) | 2015-03-03 |
| IL202840A0 (en) | 2010-06-30 |
| US20140107040A1 (en) | 2014-04-17 |
| US9504677B2 (en) | 2016-11-29 |
| US9062001B2 (en) | 2015-06-23 |
| US20150250777A1 (en) | 2015-09-10 |
| AU2008265595A1 (en) | 2008-12-24 |
| KR20100050466A (ko) | 2010-05-13 |
| WO2008157786A1 (en) | 2008-12-24 |
| US8383823B2 (en) | 2013-02-26 |
| US8969576B2 (en) | 2015-03-03 |
| US8680123B1 (en) | 2014-03-25 |
| CA2691379C (en) | 2015-06-09 |
| US20080319026A1 (en) | 2008-12-25 |
| HK1214251A1 (zh) | 2016-07-22 |
| DK2170828T3 (da) | 2013-03-04 |
| CN101842355A (zh) | 2010-09-22 |
| KR20160007684A (ko) | 2016-01-20 |
| JP2010530897A (ja) | 2010-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200407234B (en) | New inhibitors of histone deacetylase. | |
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| HRP20140195T1 (hr) | Supstituirani derivati triazolopiridazina | |
| KR20200101332A (ko) | 혈액 장애 예방 또는 치료에 있어서의 ehmt2 저해제의 사용 방법 | |
| WO2008057862A3 (en) | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF | |
| TW200738607A (en) | Sulfonamide derivatives, preparation thereof and therapeutic use thereof | |
| MX2009011208A (es) | Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5. | |
| TN2010000255A1 (en) | Organic compounds | |
| JP2015506985A5 (enExample) | ||
| HRP20201946T1 (hr) | Modulator regulatora transmembranske provodljivosti cistične fibroze, farmaceutski sastavi, postupci liječenja, i postupak za dobivanje modulatora | |
| HRP20221195T1 (hr) | Spojevi koji ciljaju psma i njihova uporaba | |
| EA200300568A1 (ru) | Гетероциклилалкилпиперидиновые производные, способ их получения и содержащие их композиции | |
| BR9509212A (pt) | Composto composição farmacêutica método de inibição de prostaglandina H sintase em um mamífero método de tratamento de uma doença inflamatória em um mamífero e método de tratamento de pirese em um mamífero | |
| EA201391558A1 (ru) | Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения | |
| YU48416B (sh) | Novi derivati hidroksamske kiseline i n-hidroksikarbamida i postupci za njihovo dobijanje | |
| JP2010514718A5 (enExample) | ||
| JP2004525174A5 (enExample) | ||
| ZA200509176B (en) | N-Alkynyl-2-(Substituted aryloxy) alkylthioamide derivatives as fungicides | |
| ATE550337T1 (de) | Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung | |
| WO2008043911A3 (fr) | Complexes chelates dendritiques, leurs procedes de fabrication et compositions pharmaceutiques les contenant | |
| DE69801379D1 (de) | Verwendung von hyperverzweigten Polymeren oder Dendrimeren mit besonderen Gruppen als filmbildendes Mittel, dieses Mittel enthaltende filmbildende Zusammensetzungen und deren Verwendung in der Kosmetik oder in der Pharmazie | |
| SG11201804636YA (en) | Composition for post chemical-mechanical-polishing cleaning | |
| WO2006081252A3 (en) | Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics | |
| JP2016521275A5 (enExample) | ||
| HRP20050830A2 (en) | Non-nucleoside reverse transcriptase inhibitors i for treating hiv mediated diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 JUN 2015 BY BALDWINS INTELLECTUAL PROPERTY Effective date: 20140624 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2016 BY COMPUTER PACKAGES INC Effective date: 20150602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2017 BY DENNEMEYER + CO Effective date: 20160520 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2018 BY DENNEMEYER + CO. Effective date: 20170522 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2019 BY DENNEMEYER + CO Effective date: 20180526 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2020 BY DENNEMEYER + CO. Effective date: 20190522 |
|
| ASS | Change of ownership |
Owner name: PURETECH LYT 100, INC., US Effective date: 20191121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2021 BY DENNEMEYER + CO. Effective date: 20200608 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2022 BY DENNEMEYER+CO. Effective date: 20210607 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2023 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20220613 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2024 BY COMPUTER PACKAGES INC Effective date: 20230530 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2025 BY COMPUTER PACKAGES INC Effective date: 20240530 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 JUN 2026 BY COMPUTER PACKAGES INC Effective date: 20250530 |